These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37185766)

  • 1. Structural, nonclinical, and clinical features of ozoralizumab: A novel tumour necrosis factor inhibitor.
    Takeuchi T
    Mod Rheumatol; 2023 Nov; 33(6):1059-1067. PubMed ID: 37185766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY
    Takeuchi T; Chino Y; Kawanishi M; Nakanishi M; Watase H; Mano Y; Sato Y; Uchida S; Tanaka Y
    Arthritis Res Ther; 2023 Apr; 25(1):60. PubMed ID: 37055803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ozoralizumab: first Nanobody® therapeutic for rheumatoid arthritis.
    Tanaka Y
    Expert Opin Biol Ther; 2023; 23(7):579-587. PubMed ID: 37431762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the anti-TNF multivalent NANOBODY® compound ozoralizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: A 52-week result of a Phase II/III study (OHZORA trial).
    Tanaka Y; Kawanishi M; Nakanishi M; Yamasaki H; Takeuchi T
    Mod Rheumatol; 2023 Aug; 33(5):883-890. PubMed ID: 36197757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of anti-TNF multivalent NANOBODY® compound 'ozoralizumab' without methotrexate co-administration in patients with active rheumatoid arthritis: A 52-week result of phase III, randomised, open-label trial (NATSUZORA trial).
    Tanaka Y; Kawanishi M; Nakanishi M; Yamasaki H; Takeuchi T
    Mod Rheumatol; 2023 Aug; 33(5):875-882. PubMed ID: 36201360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological profiles and clinical efficacy of ozoralizumab (Nanozora
    Kawanishi M; Fujii Y
    Nihon Yakurigaku Zasshi; 2023; 158(6):490-499. PubMed ID: 37914330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ozoralizumab, a Humanized Anti-TNFα NANOBODY
    Ishiwatari-Ogata C; Kyuuma M; Ogata H; Yamakawa M; Iwata K; Ochi M; Hori M; Miyata N; Fujii Y
    Front Immunol; 2022; 13():853008. PubMed ID: 35273620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ozoralizumab: First Approval.
    Keam SJ
    Drugs; 2023 Jan; 83(1):87-92. PubMed ID: 36509938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis.
    Coppieters K; Dreier T; Silence K; de Haard H; Lauwereys M; Casteels P; Beirnaert E; Jonckheere H; Van de Wiele C; Staelens L; Hostens J; Revets H; Remaut E; Elewaut D; Rottiers P
    Arthritis Rheum; 2006 Jun; 54(6):1856-66. PubMed ID: 16736523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unique structure of ozoralizumab, a trivalent anti-TNFα NANOBODY
    Kyuuma M; Kaku A; Mishima-Tsumagari C; Ogawa B; Endo M; Tamura Y; Ishikura KI; Mima M; Nakanishi Y; Fujii Y
    Front Immunol; 2023; 14():1149874. PubMed ID: 37122706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II/III Results of a Trial of Anti-Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis.
    Takeuchi T; Kawanishi M; Nakanishi M; Yamasaki H; Tanaka Y
    Arthritis Rheumatol; 2022 Nov; 74(11):1776-1785. PubMed ID: 35729713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation and Characterization of Single-Domain Antibodies from Immune Phage Display Libraries.
    Rossotti MA; Trempe F; van Faassen H; Hussack G; Arbabi-Ghahroudi M
    Methods Mol Biol; 2023; 2702():107-147. PubMed ID: 37679618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics of Ozoralizumab in Patients with Rheumatoid Arthritis.
    Takeuchi T; Chino Y; Mano Y; Kawanishi M; Sato Y; Uchida S; Tanaka Y
    J Clin Pharmacol; 2024 Apr; 64(4):418-427. PubMed ID: 37909264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation.
    Tikhonova IA; Yang H; Bello S; Salmon A; Robinson S; Hemami MR; Dodman S; Kharechko A; Haigh RC; Jani M; McDonald TJ; Hoyle M
    Health Technol Assess; 2021 Feb; 25(8):1-248. PubMed ID: 33555998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
    Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM
    Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the extended dosing interval of anti-TNF-α NANOBODY® compound ozoralizumab in patients with low disease activity rheumatoid arthritis.
    Takeuchi T; Nakanishi M; Kawanishi M; Yamasaki H; Tanaka Y
    Mod Rheumatol; 2024 Jul; 34(4):678-685. PubMed ID: 37804232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs).
    Maass DR; Sepulveda J; Pernthaner A; Shoemaker CB
    J Immunol Methods; 2007 Jul; 324(1-2):13-25. PubMed ID: 17568607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial.
    Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Walker D; Kelly C; Birrell F; Chakravarty K; Maddison P; Heslin M; Patel A; Kingsley GH
    BMJ; 2015 Mar; 350():h1046. PubMed ID: 25769495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rice-based soluble form of a murine TNF-specific llama variable domain of heavy-chain antibody suppresses collagen-induced arthritis in mice.
    Abe M; Yuki Y; Kurokawa S; Mejima M; Kuroda M; Park EJ; Scheller J; Nakanishi U; Kiyono H
    J Biotechnol; 2014 Apr; 175():45-52. PubMed ID: 24548461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.